Gaspar L, Gilbert F, Chan J S, Seidah N G, Chrétien M
Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Quebec.
Clin Invest Med. 1989 Aug;12(4):241-6.
Urinary levels of immunoreactive (IR) human NH2-terminal (hNT) of pro-opiomelanocortin were measured in 43 patients with various cell types of lung cancer (19 squamous cells, 12 oat cells, 2 large cells, and 10 adenocarcinoma), 32 patients with benign lung disease, two patients after hypophysectomy, and in 23 healthy volunteers. Lung cancer patients were divided into two subgroups according to the stage of the disease: 22 patients had "limited", and 21 patients "extensive" disease. Urinary and plasma levels were measured in 9 patients with lung cancer before and after radio- and chemotherapy or surgery. Urine samples were dialyzed and IR hNT material was extracted by Sep Pak C-18 cartridges using a propanol-2/TFA solvent system. The plasma and urinary IR hNT levels of the normal controls were 124 +/- 25 pg/ml and 47.8 +/- 14.5 pg/mg creatinine, respectively. The plasma levels of IR hNT were elevated (greater than mean + 2SD) in 65% of our patients with histologically proven lung cancer (422 +/- 775, mean +/- SD, pg/ml). The highest incidence of an elevated plasma level of IR hNT was found in oat cell carcinoma (83%). Elevated plasma IR hNT occurred in 66% of the patients with benign pulmonary disease (246 +/- 141 pg/ml, N.S.). In cancer patients with "limited" disease we found levels of 226 +/- 143 pg/ml and in patients with "extensive" disease 627 +/- 1074 pg/ml (N.S.). The urinary IR hNT level in lung cancer patients was 186 +/- 337 pg/mg creatinine and 81% of our patients had elevated levels.(ABSTRACT TRUNCATED AT 250 WORDS)
在43例患有不同细胞类型肺癌的患者(19例鳞状细胞癌、12例燕麦细胞癌、2例大细胞癌和10例腺癌)、32例患有良性肺病的患者、2例垂体切除术后患者以及23名健康志愿者中,检测了尿中阿片促黑激素皮质素原免疫反应性(IR)人氨基末端(hNT)水平。肺癌患者根据疾病分期分为两个亚组:22例患者为“局限性”疾病,21例患者为“广泛性”疾病。对9例肺癌患者在放疗、化疗或手术前后检测了尿和血浆水平。尿样经透析处理,使用丙醇 - 2/三氟乙酸溶剂系统,通过Sep Pak C - 18柱提取IR hNT物质。正常对照组血浆和尿中IR hNT水平分别为124±25 pg/ml和47.8±14.5 pg/mg肌酐。在经组织学证实的肺癌患者中,65%的患者血浆IR hNT水平升高(大于均值 + 2标准差,422±775,均值±标准差,pg/ml)。血浆IR hNT水平升高发生率最高的是燕麦细胞癌(83%)。66%的良性肺病患者血浆IR hNT水平升高(246±141 pg/ml,无统计学差异)。“局限性”疾病的癌症患者中,该水平为226±143 pg/ml,“广泛性”疾病患者中为627±1074 pg/ml(无统计学差异)。肺癌患者尿中IR hNT水平为186±337 pg/mg肌酐,81%的患者水平升高。(摘要截短于250字)